Latest research on Ezetimibe

Ezetimibe is an anti-hyperlipidemic medication which is used to lower cholesterol levels. Specifically, it appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes.

Ezetimibe indications

The statin effects on EPC activity appear to be independent of the impact on LDL-C reduction, as shown by the comparison of Simvastatin with Ezetimibe administration [69], suggesting that the beneficial effect of lipid lowering drugs on the endothelium health status may be enhanced by EPC stimulation. [source, 2016]
The LDL-lowering effects of evacetrapib were being evaluated in the multicenter “Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia” (ACCENTUATE) study (ClinicalTrials.gov Identifier: NCT02227784) [www.clinicaltrials.gov/ct2/show/NCT02227784]. [source, 2016]
To define pharmacotherapy use, participants were asked to list all current medications, allowing determination of Acetylsalicylic acid, statin, Ezetimibe, fibrate, and RAS inhibitor use; history of side-effects, drug intolerance, and duration of therapy were not ascertained. [source, 2016]
SHARP was a randomized placebo-controlled trial investigating the effects of lowering low-density lipoprotein cholesterol levels for an average of 5 years with Simvastatin, 20 mg, plus Ezetimibe, 10 mg, daily on major vascular and kidney disease outcomes. [source, 2016]
The marginally significant interaction in education gradient in CKD progression by study treatment assignment (P = 0.02) was in the absence of any overall effect of allocation to Simvastatin plus Ezetimibe on CKD progression in the study.14 [source, 2016]
Other drugs, such as dipeptidyl-peptidase 4 inhibitors [10], a PPARγ agonist (Pioglitazone) [11], Atorvastatin plus Ezetimibe [12], olmesartan [13], have also been reported to have antiatherosclerotic effects, although the effects have not been verified by large-scale studies. [source, 2016]
Recently we showed that in hypertensive patients with hyperlipidemia, Simvastatin and Ezetimibe exerted similar hypolipidemic effects, although only the statin reduced sympathetic activity [23]. [source, 2015]
Limited data suggest that Ezetimibe, whether added to a statin or used as a monotherapy, does not have an adverse effect on glucose metabolism [17,18]. [source, 2015]
This study was conducted to prospectively examine the effects of Ezetimibe on glucose metabolism in patients with type 2 diabetes and hypercholesterolemia. [source, 2015]
Several studies in animals have suggested that Ezetimibe may have positive effects on glycemic control, including reduced weight gain, diet-induced hyperglycemia and insulin resistance [22], improvement in insulin and plasma glucose response in obese fatty rats [23], and improvement in glucose tolerance, increased insulin sensitivity, and protecting the function of beta-cells in diabetic mice [24]. [source, 2015]